Tissue | VIP | PHI | BSA | ||||||
---|---|---|---|---|---|---|---|---|---|
MST | None | MST | None | MST | None | ||||
Adrenal | 24.5 ± 8.2 | 4 ± 0.8 | 87.5 ± 11.6 | 3.8 ± 1.7 | 26.8 ± 7.8 | 1.3 ± 0.2 | |||
Bladder | 31.5 ± 6.6 | 2.4 ± 0.9 | 53.9 ± 20 | 2.4 ± 0.9 | 36.5 ± 5.2 | 2.1 ± 0.8 | |||
Blood | 26.6 ± 3.3 | 1.7 ± 0.2 | 32 ± 4.9 | 2.1 ± 0.9 | 10.8 ± 0.9 | 0.7 ± 0.1 | |||
Brain | 209 ± 42.8 | 13.4 ± 4.6 | 251 ± 26.6 | 14.5 ± 6.9 | 101 ± 7.9 | 13.4 ± 2.2 | |||
Femur | 39.9 ± 6.1 | 3.4 ± 0.3 | 71.5 ± 6.7 | 5.1 ± 2.7 | 59.4 ± 23.2 | 4.9 ± 2.4 | |||
Heart | 36.5 ± 4.7 | 2.5 ± 0.2 | 58.4 ± 3.5 | 3.6 ± 1.5 | 16.7 ± 1.5 | 1.6 ± 0.3 | |||
Kidney | 1.1 ± 0.2 | 0.1 ± 0 | 3.6 ± 1.1 | 0.1 ± 0 | 11.8 ± 0.9 | 1.2 ± 0.2 | |||
Large intestine | 6.5 ± 0.5 | 0.6 ± 0.2 | 5 ± 0.9 | 0.7 ± 0.6 | 9.3 ± 1.8 | 0.7 ± 0.2 | |||
Liver | 6.9 ± 1.1 | 0.5 ± 0.1 | 13.8 ± 2.5 | 0.6 ± 0.2 | 5.7 ± 0.7 | 0.8 ± 0.2 | |||
Lung | 9.1 ± 1.4 | 0.7 ± 0.3 | 17.9 ± 4.4 | 0.8 ± 0.3 | 9.6 ± 0.7 | 0.6 ± 0.1 | |||
Muscle | 83.3 ± 10.3 | 6.1 ± 1.2 | 96.1 ± 13 | 6.1 ± 2.5 | 75.6 ± 11.4 | 5 ± 1.1 | |||
Skin | 9.8 ± 1 | 1.3 ± 0.7 | 14.8 ± 2 | 1.4 ± 0.7 | 20.8 ± 4.1 | 1.7 ± 0.4 | |||
Small intestine | 33.4 ± 4.6 | 2.7 ± 0.2 | 47 ± 7.6 | 2.8 ± 1.1 | 25.7 ± 6.4 | 1.8 ± 0.4 | |||
Spine | 56 ± 9.2 | 2.9 ± 0.2 | 79.5 ± 7 | 6.3 ± 3.2 | 30.5 ± 1.9 | 2.3 ± 0.3 | |||
Spleen | 9.8 ± 1.9 | 1.2 ± 0.2 | 37.4 ± 8.3 | 2.6 ± 1.3 | 5 ± 0.7 | 2.1 ± 0.5 | |||
Stomach | 4.7 ± 1 | 0.4 ± 0.2 | 5.3 ± 1.4 | 0.8 ± 0.4 | 8.8 ± 3 | 0.5 ± 0.2 |
T/NT ratio was calculated as follows: (%ID/g in tumor)/(%ID/g in tissue). Athymic mice (n = 5–10 per group) with xenografted NB LAN-1 were injected with standard dose of 900 μg of 5F11-scFv-SA, 450 μg of sCA, and 125I-labeled VIP, PHI, or BSA. Blood samples were obtained for kinetic studies. At 48 h, mice were killed and their organ radioactivity was measured. %ID/g for blood and various organs was calculated and T/NT ratio was expressed as mean ± SEM.